Country or Global license
Contact David Cunningham,
Account Manager,
781-972-5472
cunningham@healthtech.com

Length 
88 pages 

Date published 
August 2007 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

Add to Del.icio.us Add to furl Add to digg Add to Connotea EMail Page Printer Friendly Book Mark

Tables and Figures

Next-Generation Sequencing: Scientific and Commercial Implications of the $1000 Genome

By Kevin Davies, PhD

TABLES

Table 2.1. Next-Generation Sequencing Technologies

Table 2.2. Features of Major Next-Generation Sequencing Platforms

FIGURES

Figure 2.1. SOLiD: 2 Base Pair Encoding Using 4 Dyes

Figure 2.2. SOLiD: Example of Decoding

Figure 2.3. Apparatus for Single-Molecule Analysis Using Zero-Mode Waveguides

Figure 6.1. Survey Respondents by Sector

Figure 6.2. Primary Involvement in Next-Generation Sequencing

Figure 6.3. Application of Next-Generation Sequencing

Figure 6.4. Organisms Sequenced Using New Platform(s)

Figure 6.5. Active Use of Next-Generation Sequencing Systems

Figure 6.6. Most Promising Platform

Figure 6.7. Chief Application of Next-Generation Sequencing

Figure 6.8. Areas of Disease Research to Benefit from Next-Generation Sequencing

Figure 6.9. Chief Technical Concerns about Next-Generation Sequencing

Figure 6.10. Assessment of Current Platform Costs

Figure 6.11. Cost of Full Human Genome Sequencing by 2010

Figure 6.12. Dominant Platform

Figure 6.13. Future Role of Sanger (Capillary) Sequencing

Figure 6.14. Opinions Concerning GINA
 
 



"CHI's Insight Pharma Reports are a cost-effective and reliable source of information about the markets we serve. The cost for us to conduct this kind of business research on our own would be prohibitive. CHI's Insight Pharma Reports allow us to keep on top of developments in this rapidly moving field."

--Donald N. Halbert, ph.D., EVP of R&D, Iconix Biosciences